Yahoo Finance 4DMedical Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
4DMedical (ASX:4DX) Full Year 2023 Results
Key Financial Results
Net loss: AU$31.5m (loss widened by 28% from FY 2022).
AU$0.10 loss per share (further deteriorated from AU$0.084 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
4DMedical EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 78%. Earnings per share (EPS) exceeded analyst estimates by 3.3%.
Looking ahead, revenue is forecast to grow 97% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Healthcare Services industry in Australia.
Performance of the Australian Healthcare Services industry.
The company's shares are up 3.2% from a week ago.
Risk Analysis
We should say that we've discovered 2 warning signs for 4DMedical (1 doesn't sit too well with us!) that you should be aware of before investing here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
